Table 6.
Comparison of outcomes between the groups split based on date of cancer occurrence prior to recruitment in matched sample
| Outcome | No cancer (337) | Concurrent history of cancer < 1 year Group A (58) |
Cancer history > 1 year and < 5 years Group B (119) |
Cancer history > 5 years Group C (160) |
p-Value Group A vs Group C |
|---|---|---|---|---|---|
| Death | 129 (38.3%) | 33 (56.9%) | 67 (56.3%) | 66 (41.2%) | 0.04 |
| Cancer death | 6/52 (11.5%) | 6/17 (35.3%) | 8/30 (26.7%) | 5/29 (17.2%) | 0.16 |
| CVD death | 13/52 (25%) | 2/17 (11.8%) | 9/30 (30%) | 10/29 (34.5%) | 0.09 |
| ESRD | 87 (25.8%) | 19 (32.8%) | 24 (20.1%) | 44 (27.5%) | 0.45 |
| RRT | 65 (19.3%) | 7 (12.1%) | 14 (11.8%) | 37 (23.1%) | 0.07 |
| Transplants | 7/65 (10.8%) | 0/7 | 1/14 (7.1%) | 2/37 (7.4%) | > 0.05a |
Cause of death data was available only in 52/129 of the no cancer group, 17/33 of group A, 30/67 of group B and 29/66 of group C. CVD cardiovascular disease, ESRD end-stage renal disease, RRT renal replacement therapy. p-Value by Chi-square test, a-p-Value by Fisher Exact test. Statistically significant p-values are displayed in bold (i.e. p < 0.05)